Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners SG&A Expense (Quarterly): 5.036M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.036M |
| September 30, 2023 | 5.008M |
| June 30, 2023 | 5.191M |
| March 31, 2023 | 5.877M |
| December 31, 2022 | 5.222M |
| September 30, 2022 | 5.757M |
| June 30, 2022 | 5.678M |
| Date | Value |
|---|---|
| March 31, 2022 | 6.233M |
| December 31, 2021 | 4.978M |
| September 30, 2021 | 5.107M |
| June 30, 2021 | 4.705M |
| March 31, 2021 | 3.697M |
| December 31, 2020 | 3.177M |
| September 30, 2020 | 2.924M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.924M
Minimum
Sep 2020
6.233M
Maximum
Mar 2022
4.899M
Average
5.071M
Median
SG&A Expense (Quarterly) Benchmarks
| AC Immune SA | 5.688M |
| CRISPR Therapeutics AG | 17.95M |
| Addex Therapeutics Ltd | 1.922M |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | 6.806M |